Last reviewed · How we verify
Paromomycin Sulfate Powder
Paromomycin Sulfate Powder is a Aminoglycoside antibiotic Small molecule drug developed by University of Leipzig. It is currently in Phase 3 development for Gastrointestinal infections caused by susceptible gram-negative and gram-positive bacteria, Parasitic infections (e.g., amebiasis, cryptosporidiosis). Also known as: Metronidazole.
Paromomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Paromomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Gastrointestinal infections caused by susceptible gram-negative and gram-positive bacteria, Parasitic infections (e.g., amebiasis, cryptosporidiosis).
At a glance
| Generic name | Paromomycin Sulfate Powder |
|---|---|
| Also known as | Metronidazole |
| Sponsor | University of Leipzig |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Paromomycin sulfate is an aminoglycoside antibiotic that works by irreversibly binding to the bacterial 30S ribosomal subunit, disrupting protein synthesis and leading to bacterial cell death. It has broad-spectrum activity against gram-negative and gram-positive bacteria, as well as some activity against certain parasites. The drug is bactericidal and is commonly used for gastrointestinal infections and parasitic diseases.
Approved indications
- Gastrointestinal infections caused by susceptible gram-negative and gram-positive bacteria
- Parasitic infections (e.g., amebiasis, cryptosporidiosis)
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal discomfort)
- Ototoxicity (with systemic absorption)
- Nephrotoxicity (with systemic absorption)
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paromomycin Sulfate Powder CI brief — competitive landscape report
- Paromomycin Sulfate Powder updates RSS · CI watch RSS
- University of Leipzig portfolio CI
Frequently asked questions about Paromomycin Sulfate Powder
What is Paromomycin Sulfate Powder?
How does Paromomycin Sulfate Powder work?
What is Paromomycin Sulfate Powder used for?
Who makes Paromomycin Sulfate Powder?
Is Paromomycin Sulfate Powder also known as anything else?
What drug class is Paromomycin Sulfate Powder in?
What development phase is Paromomycin Sulfate Powder in?
What are the side effects of Paromomycin Sulfate Powder?
What does Paromomycin Sulfate Powder target?
Related
- Drug class: All Aminoglycoside antibiotic drugs
- Target: All drugs targeting Bacterial 30S ribosomal subunit
- Manufacturer: University of Leipzig — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Gastrointestinal infections caused by susceptible gram-negative and gram-positive bacteria
- Indication: Drugs for Parasitic infections (e.g., amebiasis, cryptosporidiosis)
- Also known as: Metronidazole